BLLN
BillionToOne, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$99.39
−0.11%Sep 1, 2026, 13:00 UTC
BillionToOne launched Northstar Origin, a new liquid biopsy add-on test for tissue-of-origin prediction, and expanded its Northstar Select panel from 84 to 102 genes.
Source:Aug 5, 2026, 23:05 UTC
Billiontoone reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses, and posted positive operating income and free cash flow.